The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China
In China, the data about current management of patients hospitalized with community acquired pneumonia (CAP) in the real-life setting is not available,type of pneumonia, selection of initial antibiotic, time to clinical stability, antibiotic choice anf modification,clinical outcomes and costs remain unclear. In this study, we will collect comprehensive information on CAP and healthcare associated pneumonia (HCAP) management patterns to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China .to analyze microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of patients with CAP (\> and = 65 years, different comorbidities ,risk factors) ,to investigate microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of disease severity with CAP ,to provide the difference on microbiological characteristics,clinical manifestations,antibiotic regimens ,and outcome between patients with CAP and HCAP ,to understand the current situation of antibiotic regimen ,to evaluate influence of different antibiotic regimens on prognosis.
Study Type
OBSERVATIONAL
Enrollment
3,000
China-Japan Friendship Hospital
Beijing, China
initial antibiotic treatment failure rate
a change in antibiotic therapy due to worsening signs or symptoms of infection or lack of clinical improvement after first dose use of antibiotics to 72h
Time frame: 72 hours
in-hospital clinical failure rate
1)a change in antibiotic therapy due to worsening signs or symptoms of infection or lack of clinical improvement, 2) in-hospital mortality, 3) recurrence, defined as signs or symptoms of infection after completion of therapy requiring re-initiation of antibiotics
Time frame: Time from date of admission to discharge up to 1 week
30-day post-discharge clinical failure rate
rate of re-hospitalization due to pulmonary infection and death during the follow-up period at 30 days post-discharge from hospital
Time frame: discharge up to 5 weeks
Duration of intravenous antimicrobial therapy
Time from the first dose of intravenous antibiotics to date of stop of intravenous antibiotics ,participants will be followed for the duration of hospital stay
Time frame: 2 weeks
Duration of oral antimicrobial therapy
Time from date of administration of first antibiotic to date of discontinuation of last antibiotic
Time frame: 2 weeks
Duration of antimicrobial therapy
Time from date of administration of first antibiotic to date of discontinuation of last antibiotic (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge from hospital post discharge from hospital
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Days of each antimicrobial therapy
Time from date of first administration on admission to hospital to date of discontinuation (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge follow-up for each antibiotic
Time frame: 6 weeks
Hospital length of stay
Patients will be asked about hospitalization, date, Patients will be asked about hospitalization, date, participants will be asked about the time of admission and discharge
Time frame: 2 weeks